We aimed to evaluate the role of an ATP-citrate lyase inhibitor as a novel treatment for obesity-related nephropathy by attenuating ELA in the kidney and the ensuing inflammation. The gene discussed is ACLY; the disease is obesity due to melanocortin 4 receptor deficiency.